Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2

Regulatory Toxicology and Pharmacology

Volumn 67, Issue 1, 2013, Pages 89-97

  Gould, Janet C ^a   Kasichayanula, Sreeneeranj ^a   Shepperly, David C ^a   Boulton, David W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dapagliflozin; Occupational exposure limit; Pharmacokinetics; SGLT2 inhibitors; Urinary glucose excretion

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE;

ABDOMINAL PAIN; AIR MONITORING; AIR POLLUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; FEMALE; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; LIMIT OF QUANTITATION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OCCUPATIONAL EXPOSURE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC INHALATION; WORKPLACE;

DAPAGLIFLOZIN; OCCUPATIONAL EXPOSURE LIMIT; PHARMACOKINETICS; SGLT2 INHIBITORS; URINARY GLUCOSE EXCRETION;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSIDES; GLYCOSURIA; HUMANS; KIDNEY; MALE; OCCUPATIONAL EXPOSURE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84883460374     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.07.002     Document Type: Article

References (24)

1. Bailey C.J., Gross J.L., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375(9733):2223-2233.
2. Beck B.D., Conolly R.B., et al. Improvements in quantitative noncancer risk assessment. Sponsored by the risk assessment specialty section of the society of toxicology. Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology 1993, 20(1):1-14.
3. Calado J., Loeffler J., et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney International 2006, 69(5):852-855.
4. EPA, 2002. Environmental protection agency. A review of the reference dose and reference concentration processes. EPA/600/P-02/002F. Available from: (accessed 29.09.12). http://www.epa.gov/raf/publications/pdfs/rfd-final.pdf.
5. EPA, 2011. Environmental protection agency. Exposure factors handbook EPA/600/R-090/052F, Available from: (accessed 29.09.12). http://hero.epa.gov/index.cfm?action=reference.download&reference_id=786546.
6. FDA, 2005. Guidance for industry: estimating the maximum safe dose in initial clinical trials for therapeutics in adult healthy volunteers. Available from: J:\!GUIDANC\5541fnlcln1.doc U.S. Department of Health and Human Services Food and Drug AdministrationCenter for Drug Evaluation and Research Pharmacology and Toxicology, 2005. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf.
7. Francis J., Zhang J., et al. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2004, 19(11):2893-2895.
8. Han S., Hagan D.L., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 57(6):1723-1729.
9. ICH, 2009. International committee on harmonisation of technical requirements for registration of pharmaceuticals for human use. q3c residual solvents. Appendix 3 Methods for establishing exposure limits 2009. Available from: (accessed 29.09.12). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf.
10. Kasichayanula S., Yao M., et al. Disposition and mass balance of [14C]-dapagliflozin after single oral dose in healthy male volunteers. The AAPS Journal 2008, 10:S2.
11. Komoroski B., Vachharajani N., et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharmacology and Therapeutics 2009, 85(5):520-526.
12. Komoroski B., Vachharajani N., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics 2009, 85(5):513-519.
13. Lewis S.C., Lynch J.R., et al. A new approach to deriving community exposure guidelines from "no-observed-adverse-effect-levels". Regulatory Toxicology and Pharmacology 1990, 11:314-330.
14. List J.F., Woo V., et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32(4):650-657.
15. McNamara B.P. Concepts in health evaluation of commercial and industrial chemicals. New Concepts in Safety Evaluation 1976, Hemisphere, Washington, DC. M.A. Mehlman, R.E. Shapiro, H. Blumethal (Eds.).
16. Naumann B., Weideman P. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharamceutical active ingredients. Human and Ecological Risk Assessment 1995, 5:560-613.
17. Obermeier M., Yao M., et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2010, 38(3):405-414.
18. Oemar B.S., Byrd D.J., et al. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clinical Nephrology 1987, 27(3):156-160.
19. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regulatory Toxicology and Pharmacology 1998, 27:3-20.
20. Rowland M., Tozer T.N. Clinical Pharmacokinetics, Concepts and Applications 1989, Lea & Febiger, Philadelphia. second ed.
21. Sargent E.V., Kirk G.D. Establishing airborne exposure control limits in the pharmaceutical industry. American Industrial Hygiene Association Journal 1988, 49(6):309-313.
22. Scholl-Burgi S., Santer R., et al. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2004, 19(9):2394-2396.
23. Silverman K.C., et al. Establishing data-derived adjustment factors from published pharmaceutical clinical trial data. Human and Ecological Risk Assessment 1999, 5:1059-1089.
24. Washburn W.N. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opinion on Therapeutic Patents 2009, 19(11):1485-1499.